Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity

ACS Chemical Biology

Volumn 9, Issue 3, 2014, Pages 663-672

  Sharlow, Elizabeth R ^a   Leimgruber, Stephanie ^a   Murray, Samantha ^a   Lira, Ana ^a   Sciotti, Richard J ^b   Hickman, Mark ^b   Hudson, Thomas ^b   Leed, Susan ^b   Caridha, Diana ^c   Barrios, Amy M ^c   Close, David ^d   Grögl, Max ^b   Lazo, John S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AURANOFIN; ANTIPROTOZOAL AGENT;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEISHMANIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HOST CELL; IN VITRO STUDY; LEISHMANIA; MEMBRANE PERMEABILITY; MICROBIAL GROWTH; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE SURVIVAL; PHARMACOPHORE; PRIORITY JOURNAL; PROMASTIGOTE; SCANNING ELECTRON MICROSCOPY; SKIN LEISHMANIASIS; ZOONOSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; LEISHMANIASIS; PATHOGENICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPROTOZOAL AGENTS; APOPTOSIS; AURANOFIN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; LEISHMANIA; LEISHMANIASIS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896981588     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb400800q     Document Type: Article

References (36)

1. Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters, N., Adlem, E., Tivey, A., Aslett, M., Kerhornou, A., Ivens, A., Fraser, A., Rajandream, M. A., Carver, T., Norbertczak, H., Chillingworth, T., Hance, Z., Jagels, K., Moule, S., Ormond, D., Rutter, S., Squares, R., Whitehead, S., Rabbinowitsch, E., Arrowsmith, C., White, B., Thurston, S., Bringaud, F., Baldauf, S. L., Faulconbridge, A., Jeffares, D., Depledge, D. P., Oyola, S. O., Hilley, J. D., Brito, L. O., Tosi, L. R., Barrell, B., Cruz, A. K., Mottram, J. C., Smith, D. F., and Berriman, M. (2007) Comparative genomic analysis of three Leishmania species that cause diverse human disease Nat. Genet. 39, 839-847
2. Sharlow, E. R., Grogl, M., Johnson, J., and Lazo, J. S. (2010) Anti-leishmanial drug discovery: rising to the challenges of a highly neglected disease Mol. Interventions 10, 72-75
3. WHO Expert Committee on the Control of the Leishmaniases (2010) Control of the leishmaniases: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010, World Health Organization, Geneva.
4. Ready, P. D. (2010) Leishmaniasis emergence in Europe Euro. Surveill. 15, 19505
5. Gonzalez, C., Wang, O., Strutz, S. E., Gonzalez-Salazar, C., Sanchez-Cordero, V., and Sarkar, S. (2010) Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species PLoS Neglected Trop. Dis. 4, e585
6. Clarke, C. F., Bradley, K. K., Wright, J. H., and Glowicz, J. (2013) Case report: Emergence of autochthonous cutaneous leishmaniasis in northeastern Texas and southeastern Oklahoma Am. J. Trop. Med. Hyg. 88, 157-161
7. Hotez, P. J. (2008) Neglected infections of poverty in the United States of America PLoS Neglected Trop. Dis. 2, e256
8. Grogl, M., Hickman, M., Ellis, W., Hudson, T., Lazo, J. S., Sharlow, E. R., Johnson, J., Berman, J., and Sciotti, R. J. (2013) Drug discovery algorithm for cutaneous leishmaniasis Am. J. Trop. Med. Hyg. 88, 216-221
9. Brendle, J. J., Outlaw, A., Kumar, A., Boykin, D. W., Patrick, D. A., Tidwell, R. R., and Werbovetz, K. A. (2002) Antileishmanial activities of several classes of aromatic dications Antimicrob. Agents Chemother. 46, 797-807
10. Dorlo, T. P., Balasegaram, M., Beijnen, J. H., and de Vries, P. J. (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis J. Antimicrob. Chemother. 67, 2576-2597
11. Hamill, R. J. (2013) Amphotericin B formulations: a comparative review of efficacy and toxicity Drugs 73, 919-934
12. Murray, H. W. (2012) Leishmaniasis in the United States: treatment in 2012 Am. J. Trop. Med. Hyg. 86, 434-440
13. Zerpa, O., Ulrich, M., Blanco, B., Polegre, M., Avila, A., Matos, N., Mendoza, I., Pratlong, F., Ravel, C., and Convit, J. (2007) Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses Br. J. Dermatol. 156, 1328-1335
14. Koff, A. B. and Rosen, T. (1994) Treatment of cutaneous leishmaniasis J. Am. Acad. Dermatol. 31, 693-708 quiz 708-610
15. Bern, C., Maguire, J. H., and Alvar, J. (2008) Complexities of assessing the disease burden attributable to leishmaniasis PLoS Neglected Trop. Dis. 2, e313
16. Wyatt, P. G., Gilbert, I. H., Read, K. D., and Fairlamb, A. H. (2011) Target validation: linking target and chemical properties to desired product profile Curr. Top. Med. Chem. 11, 1275-1283
17. Debnath, A., Parsonage, D., Andrade, R. M., He, C., Cobo, E. R., Hirata, K., Chen, S., Garcia-Rivera, G., Orozco, E., Martinez, M. B., Gunatilleke, S. S., Barrios, A. M., Arkin, M. R., Poole, L. B., McKerrow, J. H., and Reed, S. L. (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target Nat. Med. 18, 956-960
18. Madeira, J. M., Gibson, D. L., Kean, W. F., and Klegeris, A. (2012) The biological activity of auranofin: implications for novel treatment of diseases Inflammopharmacology 20, 297-306
19. Ilari, A., Baiocco, P., Messori, L., Fiorillo, A., Boffi, A., Gramiccia, M., Di Muccio, T., and Colotti, G. (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition Amino Acids 42, 803-811
20. Colotti, G., Ilari, A., Fiorillo, A., Baiocco, P., Cinellu, M. A., Maiore, L., Scaletti, F., Gabbiani, C., and Messori, L. (2013) Metal-based compounds as prospective antileishmanial agents: Inhibition of trypanothione reductase by selected gold complexes ChemMedChem 8, 1634-1637
21. Angelucci, F., Sayed, A. A., Williams, D. L., Boumis, G., Brunori, M., Dimastrogiovanni, D., Miele, A. E., Pauly, F., and Bellelli, A. (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects J. Biol. Chem. 284, 28977-28985
22. Rigobello, M. P., Scutari, G., Boscolo, R., and Bindoli, A. (2002) Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative Br. J. Pharmacol. 136, 1162-1168
23. Das, M., Mukherjee, S. B., and Shaha, C. (2001) Hydrogen peroxide induces apoptosis-like death in Leishmania donovani promastigotes J. Cell Sci. 114, 2461-2469
24. Sen, N., Das, B. B., Ganguly, A., Mukherjee, T., Tripathi, G., Bandyopadhyay, S., Rakshit, S., Sen, T., and Majumder, H. K. (2004) Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani Cell Death Differ. 11, 924-936
25. Paris, C., Loiseau, P. M., Bories, C., and Breard, J. (2004) Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes Antimicrob. Agents Chemother. 48, 852-859
26. Arnoult, D., Akarid, K., Grodet, A., Petit, P. X., Estaquier, J., and Ameisen, J. C. (2002) On the evolution of programmed cell death: apoptosis of the unicellular eukaryote Leishmania major involves cysteine proteinase activation and mitochondrion permeabilization Cell Death Differ. 9, 65-81
27. Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M. A., Adlem, E., Aert, R., Anupama, A., Apostolou, Z., Attipoe, P., Bason, N., Bauser, C., Beck, A., Beverley, S. M., Bianchettin, G., Borzym, K., Bothe, G., Bruschi, C. V., Collins, M., Cadag, E., Ciarloni, L., Clayton, C., Coulson, R. M., Cronin, A., Cruz, A. K., Davies, R. M., De Gaudenzi, J., Dobson, D. E., Duesterhoeft, A., Fazelina, G., Fosker, N., Frasch, A. C., Fraser, A., Fuchs, M., Gabel, C., Goble, A., Goffeau, A., Harris, D., Hertz-Fowler, C., Hilbert, H., Horn, D., Huang, Y., Klages, S., Knights, A., Kube, M., Larke, N., Litvin, L., Lord, A., Louie, T., Marra, M., Masuy, D., Matthews, K., Michaeli, S., Mottram, J. C., Muller-Auer, S., Munden, H., Nelson, S., Norbertczak, H., Oliver, K., O'Neil, S., Pentony, M., Pohl, T. M., Price, C., Purnelle, B., Quail, M. A., Rabbinowitsch, E., Reinhardt, R., Rieger, M., Rinta, J., Robben, J., Robertson, L., Ruiz, J. C., Rutter, S., Saunders, D., Schafer, M., Schein, J., Schwartz, D. C., Seeger, K., Seyler, A., Sharp, S., Shin, H., Sivam, D., Squares, R., Squares, S., Tosato, V., Vogt, C., Volckaert, G., Wambutt, R., Warren, T., Wedler, H., Woodward, J., Zhou, S., Zimmermann, W., Smith, D. F., Blackwell, J. M., Stuart, K. D., Barrell, B., and Myler, P. J. (2005) The genome of the kinetoplastid parasite, Leishmania major Science 309, 436-442
28. Moreira, W., Leprohon, P., and Ouellette, M. (2011) Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania Cell Death Dis. 2, e201
29. Sacks, D. and Noben-Trauth, N. (2002) The immunology of susceptibility and resistance to Leishmania major in mice Nat. Rev. Immunol. 2, 845-858
30. Kean, W. F. and Kean, I. R. (2008) Clinical pharmacology of gold Inflammopharmacology 16, 112-125
31. Karver, M. R., Krishnamurthy, D., Kulkarni, R. A., Bottini, N., and Barrios, A. M. (2009) Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes J. Med. Chem. 52, 6912-6918
32. Buckner, F. S. and Wilson, A. J. (2005) Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages Am. J. Trop. Med. Hyg. 72, 600-605
33. Sharlow, E. R., Close, D., Shun, T., Leimgruber, S., Reed, R., Mustata, G., Wipf, P., Johnson, J., O'Neil, M., Grogl, M., Magill, A. J., and Lazo, J. S. (2009) Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen PLoS Neglected Trop. Dis. 3, e540
34. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screening 4, 67-73
35. Lecoeur, H., Buffet, P. A., Milon, G., and Lang, T. (2010) Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major -loaded cutaneous site do not impair the acquisition of immunity Antimicrob. Agents Chemother. 54, 984-990
36. Spath, G. F. and Beverley, S. M. (2001) A lipophosphoglycan-independent method for isolation of infective Leishmania metacyclic promastigotes by density gradient centrifugation Exp. Parasitol. 99, 97-103